Aclaris Therapeutics' high P/S ratio, alongside declining re...
Aclaris Therapeutics' high P/S ratio, alongside declining revenue and the industry's predicted 49% annual growth, could be a significant risk for shareholders and potential investors.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000269b136d5f8c99.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment